| Literature DB >> 29118034 |
Hyeanji Kim1, Joonghee Kim2, Sunhwa Kim1, Si-Hyuck Kang3, Hee-Jun Kim4, Ho Kim5, Jongbae Heo5, Seung-Muk Yi5, Kyuseok Kim2, Tae-Jin Youn1, In-Ho Chae1.
Abstract
BACKGROUND: Studies have shown that long-term exposure to air pollution such as fine particulate matter (≤2.5 μm in aerodynamic diameter [PM2.5]) increases the risk of all-cause and cardiovascular mortality. To date, however, there are limited data on the impact of air pollution on specific cardiovascular diseases. This study aimed to evaluate cardiovascular effects of long-term exposure to air pollution among residents of Seoul, Korea. METHODS ANDEntities:
Keywords: air pollution; cardiovascular disease risk factors; epidemiology; particulate matter
Mesh:
Year: 2017 PMID: 29118034 PMCID: PMC5721790 DOI: 10.1161/JAHA.117.007170
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Profiles of Study Population
| Characteristics | Values |
|---|---|
| Total number of participants | 136 094 |
| Age, y | 42.05±14.83 (136 094)* |
| <45 y | 58.2 (79 245/136 094) |
| 45–54 y | 21.3 (29 006/136 094) |
| 55–64 y | 11.8 (16 174/136 094) |
| ≥65 y | 8.6 (11 669/136 094) |
| Male sex | 49.1 (66 851/136 094) |
| Income quintiles | |
| Upper | 32.4 (44 127/136 094) |
| Upper middle | 21.1 (28 712/136 094) |
| Middle | 17.7 (24 100/136 094) |
| Lower middle | 15.4 (20 957/136 094) |
| Lower | 11.3 (15 407/136 094) |
| Covered by medical aid | 2.1 (2791/136 094) |
| Hypertension | 9.8 (13 303/136 094) |
| Diabetes mellitus | 3.1 (4154/136 094) |
| Dyslipidemia | 7.5 (10 189/136 094) |
| Chronic renal failure | 0.3 (361/136 094) |
| End‐stage renal disease | 0.1 (88/136 094) |
| Ischemic heart disease | 1.4 (1881/136 094) |
| Peripheral arterial disease | 1.3 (1803/136 094) |
| Chronic obstructive pulmonary disease | 0.4 (554/136 094) |
| Malignancy | 1.0 (1367/136 094) |
| Body mass index, kg/m2 | 23.49±3.31 (95 591) |
| Underweight (<18.5) | 4.8 (4628/95 591) |
| Normal (18.5–24.9) | 65.2 (62 290/95 591) |
| Overweight (25–29.9) | 26.6 (25 395/95 591) |
| Obese (≥30) | 3.4 (3278/95 591) |
| Smoking status | |
| Never smoker | 67.3 (60 081/89 322) |
| Ex‐smoker | 8.6 (7641/89 322) |
| Current smoker | 24.2 (21 600/89 322) |
| Systolic blood pressure, mm Hg | 121.60±15.96 (95 583) |
| Diastolic blood pressure, mm Hg | 75.91±10.79 (95 581) |
| Fasting blood glucose, mg/dL | 95.51±23.31 (95 578) |
| Hemoglobin, g/dL | 13.91±1.61 (95 561) |
| Total cholesterol, mg/dL | 193.90±36.61 (95 564) |
Data are presented as mean±SD (n) or % (n/N).
Figure 1The concentrations of PM 2.5 in Seoul, 2007–2013. (A) Maps of average PM 2.5 concentrations, and (B) yearly concentrations of PM 2.5 at each monitor. PM2.5 indicates fine particulate matter ≤2.5 μm in aerodynamic diameter.
Figure 2Relationship between long exposure to PM 2.5, PM 2.5–10, CO, SO 2, and NO 2 and composite cardiovascular events. Cox regression model for cardiovascular risk in response to PM 2.5 exposure was smoothed using penalized spline methods with 3 df. The y‐axis represents the log hazard ratio (solid line). CO indicates carbon monoxide; NO2, nitrogen dioxide: O3, ozone; PM2.5, fine particulate matter ≤2.5 μm in aerodynamic diameter; PM2.5–10 indicates fine particulate matter ≤2.5 to 10 μm in aerodynamic diameter; SO2, sulfur dioxide.
Estimated HRs and 95% CIs for Cardiovascular Events According to Increased Exposure to Air Pollutants
| Unadjusted | Age, Sex‐Adjusted | Multivariable‐Adjusted (1) | Multivariable‐Adjusted (2) | |||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| |
| PM2.5, per 1 μg/m3 | ||||||||
| Composite cardiovascular events | 1.36 (1.29–1.43) | <0.001 | 1.37 (1.30–1.44) | <0.001 | 1.42 (1.33–1.51) | <0.001 | 1.41 (1.32–1.50) | <0.001 |
| All‐cause death | 1.36 (1.29–1.43) | <0.001 | 1.38 (1.31–1.45) | <0.001 | 1.34 (1.23–1.44) | <0.001 | 1.32 (1.22–1.43) | <0.001 |
| Cardiovascular death | 1.24 (1.09–1.42) | 0.0011 | 1.26 (1.11–1.44) | <0.001 | 1.38 (1.13–1.68) | 0.002 | 1.36 (1.11–1.66) | 0.003 |
| Acute myocardial infarction | 1.30 (1.16–1.46) | <0.001 | 1.33 (1.19–1.49) | <0.001 | 1.36 (1.19–1.56) | <0.001 | 1.36 (1.19–1.56) | <0.001 |
| Congestive heart failure | 1.39 (1.28–1.52) | <0.001 | 1.42 (1.31–1.55) | <0.001 | 1.46 (1.31–1.62) | <0.001 | 1.44 (1.29–1.61) | <0.001 |
| Stroke | 1.34 (1.25–1.43) | <0.001 | 1.35 (1.26–1.45) | <0.001 | 1.40 (1.28–1.52) | <0.001 | 1.39 (1.27–1.52) | <0.001 |
| Ischemic stroke | 1.37 (1.27–1.49) | <0.001 | 1.39 (1.28–1.51) | <0.001 | 1.46 (1.31–1.62) | <0.001 | 1.45 (1.31–1.61) | <0.001 |
| Hemorrhagic stroke | 1.18 (1.04–1.33) | 0.011 | 1.19 (1.05–1.35) | 0.005 | 1.23 (1.06–1.43) | 0.008 | 1.22 (1.05–1.42) | 0.009 |
| PM2.5–10, per 1 μg/m3 | ||||||||
| Composite cardiovascular events | 2.01 (1.97–2.04) | <0.001 | 1.76 (1.74–1.79) | <0.001 | 1.90 (1.85–1.95) | <0.001 | 1.91 (1.86–1.96) | <0.001 |
| All‐cause death | 1.99 (1.96–2.03) | <0.001 | 1.67 (1.65–1.70) | <0.001 | 1.69 (1.65–1.74) | <0.001 | 1.68 (1.64–1.73) | <0.001 |
| Cardiovascular death | 1.98 (1.89–2.08) | <0.001 | 1.62 (1.56–1.69) | <0.001 | 1.64 (1.54–1.76) | <0.001 | 1.63 (1.53–1.75) | <0.001 |
| Acute myocardial infarction | 2.44 (2.33–2.55) | <0.001 | 2.16 (2.07–2.25) | <0.001 | 2.13 (2.01–2.25) | <0.001 | 2.14 (2.02–2.27) | <0.001 |
| Congestive heart failure | 1.39 (1.28–1.52) | <0.001 | 1.42 (1.31–1.55) | <0.001 | 1.46 (1.31–1.62) | <0.001 | 1.44 (1.29–1.61) | <0.001 |
| Stroke | 2.11 (2.07–2.16) | <0.001 | 1.85 (1.81–1.88) | <0.001 | 2.00 (1.94–2.06) | <0.001 | 2.02 (1.96–2.09) | <0.001 |
| Ischemic stroke | 2.12 (2.07–2.17) | <0.001 | 1.82 (1.78–1.86) | <0.001 | 1.98 (1.92–2.06) | <0.001 | 2.01 (1.94–2.08) | <0.001 |
| Hemorrhagic stroke | 2.57 (2.43–2.72) | <0.001 | 2.39 (2.26–2.52) | <0.001 | 2.42 (2.26–2.59) | <0.001 | 2.46 (2.28–2.64) | <0.001 |
| CO, per IQR (0.25 ppm) | ||||||||
| Composite cardiovascular events | 1.92 (1.77–2.09) | <0.001 | 1.83 (1.69–1.98) | <0.001 | 1.79 (1.62–1.98) | <0.001 | 1.79 (1.61–1.99) | <0.001 |
| All‐cause death | 1.95 (1.79–2.12) | <0.001 | 1.83 (1.68–1.99) | <0.001 | 1.75 (1.54–1.97) | <0.001 | 1.72 (1.52–1.94) | <0.001 |
| Cardiovascular death | 2.51 (2.02–3.13) | <0.001 | 2.28 (1.84–2.81) | <0.001 | 3.07 (2.20–4.29) | <0.001 | 2.96 (2.12–4.14) | <0.001 |
| Acute myocardial infarction | 2.47 (2.06–2.97) | <0.001 | 2.32 (1.95–2.76) | <0.001 | 2.13 (1.73–2.61) | <0.001 | 2.12 (1.72–2.61) | <0.001 |
| Congestive heart failure | 1.88 (1.64–2.16) | <0.001 | 1.81 (1.58–2.08) | <0.001 | 1.84 (1.55–2.19) | <0.001 | 1.86 (1.56–2.21) | <0.001 |
| Stroke | 2.08 (1.86–2.33) | <0.001 | 1.99 (1.78–2.23) | <0.001 | 1.98 (1.72–2.28) | <0.001 | 2.00 (1.73–2.30) | <0.001 |
| Ischemic stroke | 2.06 (1.81–2.36) | <0.001 | 1.97 (1.73–2.24) | <0.001 | 1.88 (1.60–2.22) | <0.001 | 1.91 (1.62–2.25) | <0.001 |
| Hemorrhagic stroke | 2.04 (1.66–2.50) | <0.001 | 1.99 (1.62–2.43) | <0.001 | 2.22 (1.73–2.86) | <0.001 | 2.22 (1.73–2.87) | <0.001 |
| SO2, per IQR (2.54 ppb) | ||||||||
| Composite cardiovascular events | 2.06 (1.93–2.20) | <0.001 | 1.97 (1.84–2.10) | <0.001 | 1.99 (1.83–2.17) | <0.001 | 1.94 (1.78–2.11) | <0.001 |
| All‐cause death | 1.97 (1.83–2.11) | <0.001 | 1.84 (1.72–1.97) | <0.001 | 1.73 (1.56–1.93) | <0.001 | 1.73 (1.55–1.92) | <0.001 |
| Cardiovascular death | 2.02 (1.69–2.41) | <0.001 | 1.83 (1.55–2.17) | <0.001 | 1.48 (1.13–1.93) | 0.004 | 1.50 (1.14–1.96) | 0.00316 |
| Acute myocardial infarction | 1.81 (1.55–2.11) | <0.001 | 1.75 (1.51–2.04) | <0.001 | 1.83 (1.52–2.20) | <0.001 | 1.82 (1.52–2.19) | <0.001 |
| Congestive heart failure | 2.02 (1.80–2.26) | <0.001 | 1.95 (1.74–2.18) | <0.001 | 2.00 (1.73–2.31) | <0.001 | 2.00 (1.73–2.32) | <0.001 |
| Stroke | 2.25 (2.05–2.48) | <0.001 | 2.17 (1.97–2.38) | <0.001 | 2.25 (2.00–2.53) | <0.001 | 2.25 (2.00–2.54) | <0.001 |
| Ischemic stroke | 2.31 (2.07–2.58) | <0.001 | 2.20 (1.98–2.45) | <0.001 | 2.32 (2.02–2.66) | <0.001 | 2.33 (2.02–2.68) | <0.001 |
| Hemorrhagic stroke | 2.24 (1.89–2.66) | <0.001 | 2.19 (1.86–2.60) | <0.001 | 2.13 (1.73–2.62) | <0.001 | 2.13 (1.73–2.62) | <0.001 |
| NO2, per IQR (18.4 ppb) | ||||||||
| Composite cardiovascular events | 2.17 (2.01–2.34) | <0.001 | 2.06 (1.91–2.22) | <0.001 | 2.30 (2.08–2.55) | <0.001 | 2.30 (2.08–2.55) | <0.001 |
| All‐cause death | 2.05 (1.89–2.22) | <0.001 | 1.91 (1.76–2.07) | <0.001 | 1.80 (1.60–2.04) | <0.001 | 1.79 (1.59–2.03) | <0.001 |
| Cardiovascular death | 2.79 (2.26–3.45) | <0.001 | 2.47 (2.01–3.03) | <0.001 | 2.70 (1.96–3.72) | <0.001 | 2.67 (1.94–3.69) | <0.001 |
| Acute myocardial infarction | 1.73 (1.45–2.06) | <0.001 | 1.68 (1.41–2.00) | <0.001 | 1.81 (1.46–2.25) | <0.001 | 1.81 (1.46–2.25) | <0.001 |
| Congestive heart failure | 2.12 (1.86–2.43) | <0.001 | 2.05 (1.79–2.33) | <0.001 | 2.40 (2.02–2.86) | <0.001 | 2.40 (2.02–2.85) | <0.001 |
| Stroke | 2.32 (2.07–2.59) | <0.001 | 2.24 (2.01–2.50) | <0.001 | 2.64 (2.29–3.05) | <0.001 | 2.65 (2.29–3.06) | <0.001 |
| Ischemic stroke | 2.48 (2.17–2.82) | <0.001 | 2.37 (2.09–2.70) | <0.001 | 2.73 (2.30–3.24) | <0.001 | 2.74 (2.31–3.24) | <0.001 |
| Hemorrhagic stroke | 2.02 (1.66–2.46) | <0.001 | 2.00 (1.64–2.43) | <0.001 | 2.43 (1.90–3.11) | <0.001 | 2.43 (1.90–3.12) | <0.001 |
| O3, per IQR (15.9 ppb) | ||||||||
| Composite cardiovascular events | 0.65 (0.62–0.68) | <0.001 | 0.67 (0.64–0.70) | <0.001 | 0.63 (0.59–0.67) | <0.001 | 0.63 (0.63–0.73) | <0.001 |
| All‐cause death | 0.66 (0.63–0.69) | <0.001 | 0.69 (0.65–0.72) | <0.001 | 0.68 (0.63–0.73) | <0.001 | 0.68 (0.63–0.73) | <0.001 |
| Cardiovascular death | 0.58 (0.52–0.66) | <0.001 | 0.62 (0.55–0.70) | <0.001 | 0.59 (0.49–0.71) | <0.001 | 0.59 (0.49–0.71) | <0.001 |
| Acute myocardial infarction | 0.73 (0.65–0.81) | <0.001 | 0.74 (0.67–0.83) | <0.001 | 0.72 (0.63–0.82) | <0.001 | 0.71 (0.63–0.82) | <0.001 |
| Congestive heart failure | 0.69 (0.63–0.74) | <0.001 | 0.70 (0.65–0.76) | <0.001 | 0.64 (0.58–0.71) | <0.001 | 0.64 (0.58–0.71) | <0.001 |
| Stroke | 0.63 (0.59–0.67) | <0.001 | 0.64 (0.60–0.69) | <0.001 | 0.60 (0.55–0.65) | <0.001 | 0.60 (0.55–0.65) | <0.001 |
| Ischemic stroke | 0.62 (0.57–0.66) | <0.001 | 0.63 (0.59–0.68) | <0.001 | 0.60 (0.54–0.66) | <0.001 | 0.60 (0.54–0.66) | <0.001 |
| Hemorrhagic stroke | 0.69 (0.62–0.78) | <0.001 | 0.70 (0.62–0.79) | <0.001 | 0.62 (0.53–0.71) | <0.001 | 0.62 (0.53–0.71) | <0.001 |
CI indicates confidence interval; CO, carbon monoxide; HR, hazard ratio; IQR, interquartile range; NO2, nitrogen dioxide: O3, ozone; PM2.5, fine particulate matter ≤2.5 μm in aerodynamic diameter; PM2.5–10 indicates fine particulate matter ≤2.5 to 10 μm in aerodynamic diameter; ppm, parts per million, 10−6; ppb, parts per billion, 10−9; SO2, sulfur dioxide.
Multivariable‐adjusted model 1 was adjusted for age, sex, socioeconomic status, hypertension, diabetes mellitus, dyslipidemia, chronic renal failure, end‐stage renal diseases, ischemic heart disease, peripheral arterial disease, chronic obstructive pulmonary disease, and malignancy.
Multivariable‐adjusted model 2 was adjusted for the variables listed above as well as body mass index, fasting blood glucose, total cholesterol, and hemoglobin. Composite cardiovascular events were a composite of cardiovascular death, acute myocardial infarction, congestive heart failure, and stroke.
Figure 3Kaplan–Meier survival curves for composite cardiovascular events in response to long‐term exposure to ambient PM 2.5. PM2.5 indicates fine particulate matter ≤2.5 μm in aerodynamic diameter.
Figure 4Subgroup analysis for cardiovascular risk of long‐term exposure to PM 2.5. The x‐axis represents hazard ratios with 95% confidence intervals. Int P denotes interaction P value; PM2.5 indicates fine particulate matter ≤2.5 μm in aerodynamic diameter.
Population Attributable Risk Percentages and 95% CIs Associated With Selected Cardiovascular Risk Factors for Composite Cardiovascular Outcomes
| Total | Sex | Age | |||
|---|---|---|---|---|---|
| Men | Women | <65 y | ≥65 y | ||
| PM2.5 (>25.0 μg/m3) | 30.8 (24.1–37.5) | 23.7 (16.9–30.6) | 39.0 (30.9–47.2) | 31.4 (23.5–40.3) | 30.2 (23.5–37.1) |
| Hypertension | 27.2 (24.1–30.4) | 22.3 (18.6–26.1) | 33.2 (30.1–36.3) | 16.4 (13.9–18.8) | 9.4 (2.5–16.4) |
| Diabetes mellitus | 12.1 (10.2–14.1) | 11.4 (9.2–13.7) | 13.0 (10.3–15.7) | 9.4 (7.4–11.4) | 6.9 (3.9–9.9) |
| Dyslipidemia | 10.9 (9.3–12.5) | 9.1 (5.9–12.4) | 13.0 (9.9–16.1) | 9.2 (6.9–11.6) | −1.1 (−4.7 to 2.5) |
| Obesity | 11.0 (5.9–16.0) | −0.7 (−7.0 to 5.7) | 20.1 (14.7–25.4) | 16.8 (11.7–21.9) | −4.8 (−10.9 to 1.4) |
CI indicates confidence interval; PM2.5, fine particulate matter ≤2.5 μm in aerodynamic diameter.